David Hwang

David Hwang's work experience includes roles as a Board Member at binx health starting in 2022, Head of Corporate Development at Recipharm starting in 2022, and Board Member positions at Arima Genomics, Inc. from 2020 to 2022 and Molecular Assemblies, Inc. from 2018 to 2022. Earlier in their career, they held various positions at Agilent Technologies, including Managing Director - Early Stage Partnership and Agilent Investments from 2016 to 2022 and Associate Vice President, Corporate Development from 2007 to 2022. David also worked as a Manager at PMI Group, a Senior Associate at Rutberg & Company, a Principal at Argonaut Financial, Inc., and an Associate at Friedman, Turbidy & Co.

David Hwang obtained an MBA degree in Finance from Rutgers University - Newark from 1999 to 2001. Prior to that, they attended Brandeis University from 1992 to 1995. Additionally, they attended New College of Florida from 1990 to 1992, but their degree and field of study during that period are unknown.